This Plain Language Summary of Publication article (PLSP) from Future Cardiology examines the long-term effects of evinacumab, a medication approved for treating homozygous familial hypercholesterolemia (HoFH) – a rare genetic disorder that prevents the liver from effectively removing “bad” cholesterol (LDL-C) from the body. The research focused on patients over 12 years old with HoFH, who typically don’t respond well to standard cholesterol-lowering treatments and face increased risk of early heart problems. Evinacumab is approved as an add-on therapy to other LDL-C-lowering treatments, though its impact on heart attacks, stroke, or death remains unknown. The medication has varying age-based approvals across regions: from 6 months in the UK and EU/EEA, 5 years in Canada and USA, all ages in Japan, with recent approvals in Brazil and Israel.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy’ and was published in the European Heart Journal.

Visit Oxford Academic using the link to read the original article.